InvestSMART

Atomo Diagnostics Limited (ASX:AT1)

ALERT: Price-sensitive ASX Announcement for AT1
Current share price for AT1 : $0.017 -0.021 (-55.26%)+
Announcement
Release
26 Feb 2026 9:46AM
Price at Release
$0.038
Full Release
download
Summary
Atomo Diagnostics Limited (ASX: AT1) reported strong performance in H1 FY26, particularly in their HIV Self-Test and Pascal OEM businesses. The company’s revenues reached $2.18 million, marking a 6% increase from H1 FY25. Atomo secured significant orders for its HIV Self-Test kits, totaling over $1.1 million, with additional orders anticipated in Q3. The Australian Government continues to support HIV Self-Test distribution programs. Atomo also made substantial progress with its Pascal OEM business, with orders for FebriDx totaling A$1.5 million and ongoing efforts to secure a CLIA waiver in the US. The company reported a cash balance of $3.51 million as of 31 December 2025, with no debt. Atomo plans to expand its operational capacity to support growing demand, focusing on cost management while targeting further international market expansion.
Key Points
  • Revenue increased by 6% to $2.18 million in H1 FY26.
  • Significant orders for HIV Self-Test kits with government support.
  • Cash balance of $3.51 million with no debt.
  • Pascal OEM business orders surged, primarily for FebriDx.
  • Operational expansion to support increased production capacity.
  • Focus on expanding international market reach, particularly in Europe and Asia.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.